Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year MIAMI / Aug 14, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the... Read More